Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2026 17:00 ET | Source: Arax Investment Partners

Arax Leads USA Today’s List of Best Financial Advisory Firms 2026

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Arax Investment Partners (“Arax”), a national wealth management company, today announced that it has received firmwide recognition on USA Today’s list of...
April 02, 2026 08:55 ET | Source: Unity Consortium

Protecting Healthy Futures: Unity Consortium Urges Families to Prioritize Adolescent Health During Immunization Action Week

Unity® Consortium urges families to keep young people up to date on well-visits and vaccinations during Adolescent Immunization Action Week (AIAW26).
March 30, 2026 08:00 ET | Source: Arax Investment Partners

Arax Investment Partners Adds Omni Financial Advisory Group

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Arax Investment Partners (“Arax”), a national wealth management company, today announced that it has acquired Omni Financial Advisory Group (“Omni...
March 19, 2026 16:05 ET | Source: Akebia Therapeutics, Inc.

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
March 11, 2026 08:15 ET | Source: Portillo’s Inc.

Eugene I. Lee, Jr. Appointed Chairman of the Board of Portillo’s; Michael A. Miles, Jr. to Retire as of Annual Meeting

CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Portillo’s (NASDAQ: PTLO), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today announced a leadership transition...
March 11, 2026 07:53 ET | Source: Janssen Cilag International NV

La Commission européenne approuve AKEEGA® (comprimé à double action de niraparib et d’acétate d’abiratérone) pour le traitement des patients atteints d’un cancer de la prostate hormonosensible métastatique (CPHSm) présentant des mutations BRCA1/2

Le traitement par niraparib et acétate d’abiratérone démontre un retard cliniquement significatif dans la progression de la maladie, réduisant de près de moitié le risque de progression ou de décès,...